Specifically, GACAT3 is considered to be a valuable target for therapeutic intervention in GC, CRC, HCC, breast cancer, bladder cancer, NSCLC, and glioma (Pan et al., 2019). Here, GACAT3 is linked to urinary bladder carcinoma.